Affiance Financial LLC Has $1.44 Million Stock Holdings in Bio-Techne Co. (NASDAQ:TECH)

Affiance Financial LLC decreased its holdings in Bio-Techne Co. (NASDAQ:TECHFree Report) by 7.5% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 20,426 shares of the biotechnology company’s stock after selling 1,652 shares during the quarter. Affiance Financial LLC’s holdings in Bio-Techne were worth $1,438,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. CVA Family Office LLC acquired a new stake in shares of Bio-Techne during the 4th quarter worth about $31,000. Mather Group LLC. acquired a new stake in shares of Bio-Techne during the 1st quarter worth about $38,000. First Horizon Advisors Inc. increased its position in shares of Bio-Techne by 57.9% during the 4th quarter. First Horizon Advisors Inc. now owns 521 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 191 shares in the last quarter. GAMMA Investing LLC acquired a new stake in shares of Bio-Techne during the 4th quarter worth about $44,000. Finally, Federated Hermes Inc. acquired a new stake in shares of Bio-Techne during the 3rd quarter worth about $47,000. Institutional investors and hedge funds own 98.95% of the company’s stock.

Analyst Ratings Changes

TECH has been the subject of a number of recent analyst reports. Robert W. Baird increased their target price on shares of Bio-Techne from $73.00 to $81.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Bio-Techne from $85.00 to $82.00 and set a “buy” rating for the company in a research report on Thursday, April 18th. Benchmark reissued a “buy” rating and set a $95.00 price objective on shares of Bio-Techne in a report on Thursday, May 2nd. Finally, Citigroup lowered shares of Bio-Techne from a “buy” rating to a “neutral” rating and set a $85.00 price objective on the stock. in a report on Wednesday, May 22nd. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Bio-Techne presently has an average rating of “Moderate Buy” and an average target price of $81.00.

Get Our Latest Stock Analysis on TECH

Bio-Techne Trading Down 0.7 %

Shares of NASDAQ TECH traded down $0.50 during mid-day trading on Thursday, hitting $71.60. The company’s stock had a trading volume of 39,186 shares, compared to its average volume of 1,062,924. The stock has a market cap of $11.28 billion, a price-to-earnings ratio of 57.22, a price-to-earnings-growth ratio of 8.78 and a beta of 1.29. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.08 and a quick ratio of 2.88. Bio-Techne Co. has a one year low of $51.79 and a one year high of $89.91. The company’s fifty day simple moving average is $75.43 and its 200-day simple moving average is $73.02.

Bio-Techne (NASDAQ:TECHGet Free Report) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.03. The company had revenue of $303.43 million for the quarter, compared to analyst estimates of $292.36 million. Bio-Techne had a net margin of 17.59% and a return on equity of 13.60%. The company’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.47 EPS. On average, sell-side analysts anticipate that Bio-Techne Co. will post 1.56 earnings per share for the current fiscal year.

Bio-Techne Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 24th. Investors of record on Monday, May 13th were paid a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a yield of 0.45%. The ex-dividend date of this dividend was Friday, May 10th. Bio-Techne’s payout ratio is 25.40%.

Bio-Techne Company Profile

(Free Report)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.

Featured Articles

Institutional Ownership by Quarter for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.